Skip to Main Content


What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Principal Investigator
Alexander Chi
Jiangsu Provincial Cancer Hospital
Position Title
Foreign Expert and Team Leader
About this CDAS Project
NLST (Learn more about this study)
Project ID
Initial CDAS Request Approval
Jun 18, 2020
Treatment selection and outcome of CT-screened early-stage non-small cell lung cancer
In 2020, lung cancer remains the leading cause of cancer and cancer-related mortality worldwide. It is most likely to be cured when identified in its early stages. The National Lung Cancer Screening Trial and other screening trials have shown that more lung cancer cases can be identified in earlier stages with CT screening, which can lead to a significant reduction in lung cancer mortality in high-risk patients. However, how this has impacted the selection of definitive treatments for early-stage lung cancer, mainly consisted of stage I non-small cell lung cancer(NSCLC), and treatment outcome has not been thoroughly studied. However, this may have a significant clinical impact on the management of early stage NSCLC, given the increased clinical application of lesser invasive surgeries, and non-invasiveness treatments, such as stereotactic body radiation therapy (SBRT) or radio-frequency ablation (RFA). Because how to select patients for less invasive definitive treatments remains to be more clearly defined, as prospective data on how these treatments compare to each other remains lacking.

Under the above circumstances, we'd like to propose the following aims for our study:
1) Analyze how the CT-screening identified early stage non-small cell lung cancer (clinical T1-T3, N0, M0) were treated,
and the treatment outcome.
2) Analyze how the treatment selected, and treatment related characteristics are related to cancer pathological
features, and CT features.
3) Establish correlation between CT features, tumor pathological features, and the type and extent of treatment
required for the most optimal outcome.


1. Sijin Wen. PhD. Associate Professor, Department of Biostatistics, West Virginia University.
2. Qilu Yu. PhD. Lead Biostatistician at the Office of Clinical and Regulatory Affairs, National Center for
Complementary and Integrative Health, National Health Institute.